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Abstract
Hypoxia-inducible factor (HIF), an important mediator of hypoxia response, is implicated in tumorigenesis in the setting of pseudohypoxia, 
such as in the inactivation of von Hippel–Lindau tumor suppressor protein (pVHL), leading to development and progression of clear cell renal 
cell carcinoma (ccRCC). Targeting downstream molecules in HIF pathway, such as vascular endothelial growth factor (VEGF), has led to 
improvement in clinical outcome for patients with advanced ccRCC, but such therapy thus far has been limited by eventual resistance and treat-
ment failure. Following the discovery of HIF-2α playing a key role in ccRCC carcinogenesis, inhibitors targeting HIF-2α have been developed 
and have demonstrated encouraging efficacy and safety profile in clinical trials. This review discusses HIF-2α as a promising therapeutic target 
for ccRCC. 
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Renal cell carcinoma (RCC) is the most common type of 
kidney cancer, accounting for 90% of all kidney cancers (1). 
Clear cell renal cell carcinoma (ccRCC) is the most com-
mon subtype of RCC, accounting for approximately 75% 
of patients (2). The earliest genetic event in most ccRCC is 
a loss-of-function mutation in von Hippel–Lindau (VHL) 
tumor suppressor gene (3). Loss of both VHL gene alleles 
through deletion, mutation, or other mechanisms results in 
loss of function of von Hippel–Lindau tumor suppressor 
protein (pVHL). This leads to the upregulation of hypox-
ia-inducible factor (HIF) and resultant overexpression of 
hypoxia-inducible genes, such as vascular endothelial growth 
factor (VEGF), platelet-derived growth factor-β (PDGF-β), 
and transforming growth factor-α (TGF-α) (VHL-HIF-
VEGF axis), that are involved in tumorigenesis and progres-
sion of ccRCC (4). 
BODY
Regulation of HIF-1α and HIF-2α 
Hypoxia-inducible factor is a transcription factor com-
posed of oxygen-sensitive alpha subunit (HIF-α) and con-
stitutively expressed beta subunit (HIF-b), which is also 
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known as aryl hydrocarbon receptor nuclear translocator 
(ARNT) (5). There are three isoforms of the alpha subunit: 
HIF-1α, HIF-2α, and HIF-3α. Of these three, the first two 
are the best studied isoforms. HIF-1α and HIF-2α each has 
two transactivation domains (TAD), one at the NH2 termi-
nal (N-TAD) and another at the COOH terminal (C-TAD). 
C-TAD interacts with p300/cAMP-response element binding 
protein (CREB)-binding protein (CBP) to modulate tran-
scription in hypoxic conditions. N-TAD stabilizes HIF-α 
against degradation (5). Oxygen-dependent degradation 
domain (ODDD) is positioned within N-TAD and contains 
specific proline residues (4). Variability between HIF-1α 
and HIF-2α is observed mostly within N-TAD (6), whereas 
C-TADs between HIF-1α and HIF-2α isoforms have 67% 
similarity and promote the expression of their common tar-
get genes (7).
HIF-1α and HIF-2α are finely regulated in response to dif-
ferent oxygen states. In normoxic conditions, both HIF-1α 
and HIF-2α are degraded via the pVHL/E3-ubiquitin ligase 
pathway (5). The proline residues in ODDD are hydroxyl-
ated by proline hydroxylases (PHDs), which are then bound 
by pVHL/E3-ubiquitin ligase complex. Ubiquitin ligase adds 
poly-ubiquitin to HIF-α and marks it for proteasomal deg-
radation (5). 
In hypoxic conditions, PHD loses its activity and prevents 
VHL binding, leading to stabilization and accumulation of 
HIF-α (4). In pseudo-hypoxic conditions, pVHL is inacti-
vated due to loss-of-function mutation, which also leads to 
accumulation of HIF-α (8). HIF-α then translocates into the 
nucleus, where it heterodimerizes with HIF-b and recruits 
p300/CBP co-activators to form an active HIF transcrip-
tion complex (4). This complex binds to hypoxia response 
elements (HREs) on hypoxia-sensitive genes and activates 
transcription (4). Activation of HIF transcription leads to 
upregulation of hypoxia-inducible genes such as VEGF (2). 
These genes are involved in processes such as cellular metab-
olism, glucose transport, angiogenesis, erythropoiesis, iron 
metabolism, pH regulation, apoptosis, and cell proliferation, 
thus promoting and leading to the progression of ccRCC (5). 
Switch from HIF-1α- to HIF-2α-dependent transcription 
is the result of hypoxia-associated factor (HAF) activity (6). 
HAF is a HIF-1α-specific E3 ligase that causes HIF-1α 
ubiquitination and proteasomal degradation. HAF also 
increases transcriptional activity of HIF-2α, independent of 
its E3 ligase activity. HAF level decreases in acute hypoxia, 
allowing HIF-1α to predominate, but HAF level increases 
in chronic hypoxia, which is mediated predominantly by 
HIF-2α (6). The HIF pathway focusing here on HIF-2α is 
illustrated in Figure 1.
There are other mechanisms for stabilization of HIF that 
involve inhibition of PHDs. Mutations in succinate dehydro-
genase (SDH) and fumarate hydratase (FH) genes, which are 
Kreb’s cycle enzymes and act as tumor suppressor genes, lead 
to the accumulation of succinate and fumarate, respectively, 
in the cytosol. Succinate and fumarate inhibit PHDs and 



































Figure 1: HIF-2α pathway.
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proto-oncogene c-Myc (14). Expression of HIF-2α upregu-
lates proteins involved in cell proliferation (cyclin D1), cell 
growth (TGF-α), and angiogenesis (VEGF) (14). Expression 
of HIF-2α can lead to a more oxidative tumor phenotype, 
which in turn promotes a more aggressive tumor with height-
ened treatment resistance (14). For instance, HIF-2α leads 
to lower PDK and higher PDH, leading to more oxidative 
phosphorylation, rather than glycolysis (14). 
In the context of ccRCC associated with VHL’s loss of 
function, it appears that HIF-2α plays a key role in car-
cinogenesis. Forced expression of HIF-2α, not HIF-1α, 
antagonizes pVHL’s tumor-suppressor activity in nude mice 
models (14). Studies have shown that many ccRCC cell lines 
have sustained homozygous deletions that specifically inacti-
vate HIF-1α and solely produce HIF-2α (15), which suggests 
that HIF-2α, not HIF-1α, is essential for carcinogenesis of 
ccRCC. It was also observed that ccRCC tumors express-
ing only HIF-2α were larger and more resistant to replica-
tive stress compared to those that express both HIF-1α and 
HIF-2α (14). 
While HIF-2α functions as a driver of tumorigenesis, 
HIF-1α appears to act as a tumor suppressor (16). HIF-1α 
positively regulates Bcl2 interacting protein (BNip3), a mem-
ber of the Bcl-2 family of pro-apoptotic proteins having 
anti-tumorigenic properties (12). Another important media-
tor in tumorigenesis is interleukin 8 (IL-8), which promotes 
angiogenesis and is associated with treatment resistance (17). 
HIF-1α decreases expression of IL-8 via downregulation of 
nuclear factor erythroid 2-related factor 2 (Nrf2) and c-Myc 
and upregulation of max-interacting protein 1 (Mxi-1), a 
c-Myc antagonist; on the other hand, HIF-2α upregulates 
IL-8 expression by increasing Sp-1 and c-Myc activity (6). 
See Table 1.
to their stabilization. This also creates a pseudohypoxic state 
in which hypoxia response pathways are aberrantly activated 
in spite of normoxic conditions (6). Germline FH mutations 
are implicated in hereditary leiomyomatosis and renal cell 
carcinoma (HLRCC) syndrome. Additionally, similar mech-
anisms of HIF stabilization are seen with mutations in suc-
cinate dehydrogenase complex assembly factor 2 (SDHAF2), 
hypoxia-inducible factor prolyl hydroxylase 1/2/Egl-9 homo-
log½ (EGLN1/2), and endothelial PAS domain-containing 
protein 1 (EPAS1) genes (9).
Role of HIF-2α in ccRCC carcinogenesis
The constitutive activation of the VHL-HIF-VEGF axis is 
the key mechanism of ccRCC carcinogenesis (2). Inactivation 
of VHL gene, which is almost always the first step in ccRCC 
carcinogenesis (10), leads to stabilization and transcription 
of HIF, creating a pseudohypoxic state. Transcription of 
HIF, and HIF-2α in particular, leads to overexpression of 
hypoxia-inducible genes, including VEGF, PDGF-β, TGF-a, 
c-Met, cyclin D1, and stromal cell-derived factor 1 (SDF1) 
and its receptor CXC chemokine receptor 4 (CXCR4) (10), 
which are involved in tumor angiogenesis, cell proliferation, 
survival, metabolism, invasion, metastasis, therapy resis-
tance, inflammation, and immunity (4).
While HIF-1α and HIF-2α share a similar protein struc-
ture, they have several significant differences in hypoxia 
response and gene regulation. HIF-1α predominantly 
mediates response to acute hypoxia, whereas HIF-2α medi-
ates response to chronic hypoxia (6, 11). Likewise, the two 
isoforms of HIF-α have different gene targets and regu-
latory functions. For example, while both carbonic anhy-
drase IX (CAIX) and glucose transporter 1(GLUT-1) are 
overexpressed in many forms of cancer, including RCC, 
CAIX was found to be negatively regulated by HIF-1α, 
whereas GLUT-1 was found to be a specific HIF-2α target 
in VHL-defective RCC (12). Important differences between 
HIF-1α and HIF-2α are highlighted in Table 1. 
HIF-1α is primarily involved in glucose metabolism, 
upregulating glycolytic enzymes while limiting pyruvate 
uptake by mitochondria and downregulating electron trans-
port chain (ETC) activity (13). Most epithelial cancer cells 
rely on HIF-1α transcriptional products to mediate tumor 
metabolism such as Warburg effect, which leads to repro-
gramming of tumor cells from mitochondrial respiration via 
oxidative phosphorylation to glycolysis. Pyruvate dehydroge-
nase (PDH), a key enzyme that links glycolysis to TCA cycle, 
is negatively regulated by pyruvate dehydrogenase kinase 
(PDK). HIF-1α leads to high levels of PDK and thus low 
levels of PDH, leading to more glycolysis and anaerobic 
metabolism (14).
In contrast, HIF-2α is uniquely involved in tumor 
growth and cell cycle progression through interaction with 
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VHL disease and HIF 
VHL disease is a hereditary disease transmitted in an auto-
somal dominant fashion that is caused by mutation of VHL 
gene and leads to the formation of tumors in multiple organs, 
including central nervous system (CNS) hemangioblastomas, 
RCCs, pheochromocytomas, and pancreatic neuroendocrine 
tumors (PNETs) (18). CNS hemangioblastomas are among 
the most common tumors found in patients with VHL dis-
ease, most commonly affecting the cerebellum, brainstem, 
spinal cord, and retina (18). As discussed earlier, HIF is 
upregulated by loss-of-function mutation in VHL gene and 
in turn pVHL, resulting in increased expression of numer-
ous genes implicated in tumorigenesis, including VEGF. This 
pVHL-HIF-VEGF pathway is responsible for tumorigene-
sis in not only RCC but also CNS hemangioblastomas and 
PNETs in VHL disease (18). Thus far, VEGF inhibitors have 
been shown to demonstrate limited efficacy in treatment of 
CNS hemangioblastomas. Pazopanib, a multikinase inhibi-
tor, was studied in a phase-II trial of patients with VHL-as-
sociated lesions (NCT01436227) (19). While responses 
were seen in 52% of RCCs and 53% of PNETs, only 4% of 
patients with CNS hemangioblastomas showed response 
(19). Sunitinib, another multikinase inhibitor, was studied 
in patients with VHL disease, and led to partial response in 
33% of RCCs but none in hemangioblastomas  (20). Theo-
retically, targeting the upstream molecule such as HIF-2α 
will be more effective than VEGF receptors inhibition in 
treating VHL disease. There is growing optimism that novel 
HIF-2α inhibitors will improve outcomes in patients with 
VHL- associated lesions, including non-renal lesions such as 
hemangioblastomas. The efficacy and safety data and poten-
tial role of HIF-2a inhibitors in VHL disease is discussed 
below in detail.
Treatment resistance and development  
of HIF-2a inhibitor in ccRCC 
After the discovery of VHL-HIF-VEGF axis and its role 
in ccRCC carcinogenesis, multiple agents have been devel-
oped to inhibit specific molecular targets in the HIF path-
way. For instance, VEGF inhibitors, such as sunitinib and 
cabozantinib, have been developed to target the gene prod-
uct VEGF, which is downstream in the HIF pathway (9), 
and they remain the mainstay of current ccRCC treatment. 
Other drugs (everolimus and temsirolimus) targeting phos-
phoinositide 3-kinase/protein kinase B/mechanistic target of 
rapamycin (PI3K/AKT/mTOR) pathway have been devel-
oped and gained regulatory approval for the treatment of 
advanced RCC (17). 
However, these treatment strategies are limited by eventual 
development of treatment resistance (9). Inhibition of one 
part of HIF pathway may trigger compensatory mechanisms 
that overproduce other alternative proangiogenic factors, 
leading to drug resistance. For example, in ccRCC, inhibi-
tion of one angiogenic factor (e.g., VEGF) may lead to an 
increase in the expression of other angiogenic factors (e.g., 
interleukin 6 [IL-6], IL-8, monocyte chemoattractant protein 
1 [MCP-1], and basic fibroblast growth factor [bFGF]), lead-
ing to upregulation of angiogenesis, rather than its downreg-
ulation (6). Similarly, studies involving HIF-1α inhibitors, 
which were developed in a hope of improved control of 
advanced ccRCC by targeting the HIF pathway more prox-
imally, showed that inhibition of HIF-1α may lead to com-
pensatory upregulation of HIF-2α, which can inadvertently 
lead to more neo-angiogenesis and tumor progression (4, 6). 
One strategy to overcome treatment resistance is to combine 
therapeutic agents with different molecular targets, such as 
combining different tyrosine kinase inhibitors (TKIs) with 
each other or with mTOR inhibitors. Other strategies involve 
combination of TKIs with immune checkpoint inhibitors 
such as programmed cell death protein 1 (PD-1) inhibitors, 
programmed death ligand 1 (PD-L1) inhibitors, and cyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) inhibi-
tors (17).
In addition to investigating different combination regi-
mens to circumvent treatment resistance, recent studies have 
focused on developing new therapeutic agents with novel 
molecular targets. Given the evidence that HIF-2α is the 
main driver of tumorigenesis in ccRCC (14, 21), as well as 
the theoretical advantage of targeting the VHL-HIF-VEGF 
pathway more upstream, there has been growing interest in 
the therapeutic benefit of HIF-2α inhibition. HIF-2α was 
initially thought of as an undruggable target, but the struc-
ture-activity relationship study of small molecules designed 
to inhibit HIF-2α-ARNT heterodimerization led to the 
development of inhibitors that target HIF-2α (22). PT2399 
and PT2385, the first HIF-2α inhibitors being developed, 
inhibit dimerization of HIF-2α and ARNT1 and HIF-2α- 
dependent transcription (23). PT2399 was shown to dis-
sociate specifically HIF-2α in vitro, resulting in reduced 
expression of HIF-2α target genes but not HIF-1α target 
genes in human ccRCC cell lines. This was reviewed by Chen 
et al. (23). There was reported resistance to PT2399 already. 
It was shown that in resistant tumors, even though there was 
evidence of HIF-2α disassembly, most of its target genes 
were left unaffected. Experiments in RCC cell lines suggested 
that tumor protein P53 (TP53) mutations may confer resis-
tance to HIF-2α inhibitors, but the extent to which these 
mutations result in resistance remains to be determined (24).
PT2385, a close analog of PT2399, was studied in a 
phase-I clinical trial that evaluated maximum tolerated dose 
in patients with locally advanced or metastatic ccRCC and 
Eastern Cooperative Oncology Group (ECOG) performance 
score of 0 or 1 who suffered disease progression despite pre-
vious treatment with a VEGF inhibitor (18). PT2385 did 
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(15%) were the most common grade-3 adverse reactions. No 
grade-4/5 drug-related adverse events were observed; 4% of 
patients discontinued treatment due to drug toxicity. It was 
concluded that MK-6482 was well tolerated with a favorable 
safety profile and demonstrated promising single-agent activ-
ity in heavily pretreated patients with ccRCC across Interna-
tional Metastatic RCC Database Consortium (IMDC) risk 
groups (23). A phase-III trial in a similar population is cur-
rently ongoing (Table 2). 
A phase-II trial evaluating MK-6482 showed promis-
ing clinical activity in treatment-naïve patients with VHL- 
associated non-metastatic ccRCC (24). Most common 
non-renal lesions were CNS hemangioblastomas (80.3%) and 
pancreatic lesions (50.8%). ORR was 27.9% (17/61), and effi-
cacy was durable in both RCC and non-renal lesions. Com-
plete responses were observed in 6.6% (4/61) of pancreatic 
lesions and 11.6% (5/43) of CNS hemangioblastomas  (24). 
The median DOR and median PFS were not reached. Most 
adverse events were of grade-1 or grade-2, and the most 
common adverse events included anemia (83.6%), fatigue 
(49.2%), and dizziness (21.3%). Grade-3 adverse events 
occurred in 9.8% of patients. There were no grade-4 or 
grade-5 events. Based on this data, the US Food and Drug 
Administration (FDA) granted breakthrough therapy desig-
nation to MK-6482 for the treatment of patients with VHL 
disease-associated RCC with non-metastatic RCC tumors of 
less than 3 cm in size, unless immediate surgery is required. 
The FDA also granted orphan drug designation to MK-6482 
for VHL disease. 
Selected clinical trials studying the HIF-2a inhibitors are 
summarized in Table 2. 
not cause dose-limiting toxicity at any dose level tested and 
was shown to have a favorable safety profile. Most adverse 
events were of grade 1 or grade 2, which included anemia 
(45%), peripheral edema (39%), and fatigue (37%). The 
most common adverse events that were of grade 3 or grade 
4 included anemia (10%), hypoxia (10%), and lymphopenia 
(8%). Adverse events did not lead to discontinuation in treat-
ment or death in any of the patients. Unlike VEGF inhibi-
tors, PT2385 did not lead to hypertension, thromboembolic 
events, or other cardiotoxicity. Likewise, PT2385 showed 
promising efficacy in patients who have already received mul-
tiple treatments for ccRCC, with complete response (CR) of 
2%, partial response (PR) of 12%, and stable disease (SD) 
in 52% of patients (18). Disease control rate (CR + PR + 
SD) was 66%, and 42% of patients had SD, PR, or CR for 
at least 4 months. At a median follow-up of 17.5 months, 
25% of patients had a progression-free survival (PFS) of 
>14 months. However, PT2385 was shown to have variable 
pharmacokinetics (25), with greater exposure correlated with 
longer PFS (21).
PT2977 (also known as MK-6482) is a second-genera-
tion HIF-2a inhibitor that has improved pharmacokinetic 
profile, selectivity, and potency than PT2385 (22). Phase-I/
II trial evaluated the safety and efficacy of MK-6482 in 55 
patients with previously treated advanced ccRCC (23). Most 
patients (67%) had received prior treatment with VEGF 
inhibitor and immune checkpoint inhibitor. Overall response 
rate (ORR) was 24%. Thirty-one patients (56%) had SD, 
and the disease control rate was 80%. The median duration 
of response (DOR) was not reached at the time report. The 
median PFS was 11 months. Anemia (26%) and hypoxia 
Table 2: Selected clinical trials using HIF-2 inhibitors in clear cell renal cell carcinoma (ccRCC) and other tumors.
Title of the trial Cancer type Phase Primary 
endpoint
Trial identifier
A phase-I, dose-escalation trial of PT2385 tablets in patients 
with advanced ccRCC
ccRCC I MTD NCT02293980





PT2385 for the treatment of VHL disease-associated ccRCC ccRCC II ORR NCT03108066
A phase-II study of MK-6482 (PT2977) for the treatment of 
VHL disease-associated RCC (MK6482-004) 
RCC II ORR NCT03401788
A study of MK-6482 in combination with lenvatinib versus 
cabozantinib for treatment of RCC (MK-6482-011) 
ccRCC III PFS, OS NCT04586231
A study of MK-6482 versus everolimus in patients with 
advanced RCC (MK-6482-005) 
ccRCC III PFS, OS NCT04195750
Source: https://doi.org/clinicaltrials.gov. Accessed October 30, 2020.
MTD: maximum tolerated dose; ORR: overall response rate; PFS: progression-free survival; OS: overall survival.
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Future Perspective
HIF-2α is now considered as a novel druggable target for the 
treatment of ccRCC. Given the favorable safety profile and 
efficacy of HIF-2α inhibitors, the clinical trials combining 
HIF-2α inhibitors with TKI, immune checkpoint inhibitors, 
or other antiangiogenic agents are on the way, and are prom-
ising. The future research needs to focus on better under-
standing of mechanisms of resistance to HIF-2α inhibitors. 
The regulation of tumor microenvironment and its associ-
ated biomarker research are keys for patient selection and 
success of treatment. 
Conclusion
HIF is the key mediator of oxygen hemostasis, which can be 
aberrantly activated in pseudohypoxic conditions such as in 
pVHL-defective ccRCC. HIF-2α, not HIF-1α, is the main 
driver of carcinogenesis in ccRCC. HIF-2α as a novel tar-
get for the treatment of ccRCC is established, and inhibitors 
to this pathway are being developed actively. Instead of tar-
geting endothelial cell VEGF pathway with TKIs, HIF-2α 
inhibitors target more proximally and directly the tumor cell 
HIF pathway. Early-phase clinical trials involving HIF-2α 
inhibitors have already shown promising efficacy in the treat-
ment of advanced ccRCC. 
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